Clinical Trial Update: A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Bolt Biotherapeutics is conducting a first-in-human Phase 1/2 study of BDC-4182 as a single-agent therapy in metastatic gastric adenocarcinoma and gastroesophag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Adenocarcinoma

Drugs mentioned

• BDC-4182

Snippet

Sponsor: Bolt Biotherapeutics, Inc. | Conditions: Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING